Corticosteroids Therapy Market by Drug Type (Budesonide, Dexamethasone, Hydrocortisone), Route Of Administration (Inhalation, Injectable, Oral), Dosage Form, Indication, Patient Age Group - Global Forecast 2025-2032
Description
The Corticosteroids Therapy Market was valued at USD 5.26 billion in 2024 and is projected to grow to USD 5.62 billion in 2025, with a CAGR of 7.99%, reaching USD 9.73 billion by 2032.
A comprehensive introduction to corticosteroid therapy outlining mechanisms of action, clinical indications, safety considerations, and strategic implications
Corticosteroid therapy remains a cornerstone across a wide range of inflammatory and immune-mediated conditions, with clinical practice centering on balancing therapeutic efficacy against safety and long-term risk mitigation. This introduction frames corticosteroids through their pharmacologic mechanisms of action, including glucocorticoid receptor modulation and downstream effects on gene transcription that limit pro-inflammatory cytokine production. It also situates corticosteroids within current therapeutic paradigms where they are used both as acute rescue medications and as components of chronic disease management, highlighting the importance of route selection, formulation innovation, and stewardship to reduce adverse effects.
Transitioning from mechanism to practice, this section explores how clinicians evaluate benefit–risk when selecting inhaled, oral, topical or injectable corticosteroids, and how patient factors such as age, comorbidities, and concomitant therapies influence regimen design. It also underscores operational considerations for supply chain continuity, formulation stability, and regulatory compliance that underpin reliable therapy delivery. Finally, the introduction sets expectations for the subsequent sections by outlining the intersections between clinical evolution, commercial strategy, and policy dynamics that will determine how corticosteroid therapy is delivered and optimized across care settings.
Emerging clinical advances, formulation innovations, and regulatory recalibrations reshaping corticosteroid therapy delivery and patient care decision frameworks
The corticosteroid landscape is experiencing transformative shifts driven by advances in formulation science, changing regulatory emphasis on safety and appropriate use, and improvements in delivery technologies that increase therapeutic precision. In recent years, the industry has accelerated development of targeted inhalation devices, fine-tuned topical formulations with enhanced skin tolerability, and optimized parenteral options that facilitate outpatient administration, thereby broadening the contexts in which corticosteroids can be deployed effectively. These changes reduce systemic exposure for many indications and make it possible to tailor therapy more closely to disease biology and patient preferences.
Concurrently, regulators and professional societies have placed stronger emphasis on stewardship, appropriate tapering protocols, and monitoring of cumulative steroid exposure. This has catalyzed clinical guidance updates and influenced prescriber behavior, encouraging dose minimization where possible and the adoption of nonsteroidal adjuncts. Commercially, pharmaceutical developers are responding with differentiation strategies that emphasize improved safety profiles, convenience of use, and lifecycle management through combination products or device-enabled delivery. Taken together, these forces are reshaping how corticosteroid therapies are developed, positioned, and utilized across care pathways, with implications for clinical outcomes, patient experience, and organizational strategy.
Assessment of how 2025 United States tariff adjustments influence corticosteroid supply chains, import dependencies and manufacturing strategies
Policy shifts in tariff regimes and trade policy can exert rapid effects on pharmaceutical supply chains and the movement of active pharmaceutical ingredients and finished products. In 2025, adjustments to tariff schedules present potential disruptions for companies that rely on cross-border sourcing of corticosteroid APIs, excipients, and specialized packaging. Changes in import duties will influence procurement strategies, prompting manufacturers and distributors to reassess supplier diversity, nearshoring options, and third-party logistics arrangements to preserve continuity of supply and control input costs.
As a consequence, stakeholders are placing greater emphasis on supply chain mapping, visibility into supplier tier risks, and contractual mechanisms that mitigate exposure to sudden cost shifts. Regulatory compliance and tariff classification reviews are becoming routine elements of commercial planning, and organizations are strengthening scenario planning capabilities to respond to customs adjustments or administrative delays. From a clinical perspective, procurement stability is critical because any interruption to product availability can necessitate rapid therapeutic substitutions, with attendant impacts on dosing, monitoring, and patient adherence. Overall, tariff-related dynamics in 2025 are accelerating strategic shifts toward supply resilience, diversified sourcing, and operational flexibility across the corticosteroid value chain.
Strategic segmentation analysis revealing differentiated clinical, formulation, administration route, dosage, and demographic drivers shaping corticosteroid therapy
A nuanced segmentation framework reveals how therapeutic choice and service delivery are shaped by administration route, indication, drug type, dosage form, and patient age group. When considering route of administration, inhalation approaches including dry powder inhaler, metered dose inhaler and nebulizer are prioritized for airway diseases where targeted pulmonary deposition reduces systemic exposure, while injectable options such as intramuscular, intravenous and subcutaneous routes are selected for rapid systemic control or for settings requiring parenteral therapy. Oral formulations differentiated into suspension and tablet support convenience and chronic dosing, and topical preparations in cream, lotion and ointment formats allow localized management of dermatological conditions.
Indication-based segmentation spans allergic rhinitis, asthma, dermatological disorders, inflammatory bowel disease and rheumatoid arthritis, and the clinical imperatives for efficacy and safety differ markedly across these diagnoses. Drug-type differentiation among budesonide, dexamethasone, hydrocortisone, methylprednisolone and prednisone reflects distinct potency, half-life and receptor affinities that drive dosing strategies and monitoring needs. Dosage form distinctions across cream, injection, suspension and tablet have implications for pharmacokinetics and patient adherence, while patient age group segmentation across adult, geriatric and pediatric populations necessitates tailored dosing, safety surveillance and formulation design. Collectively, these segmentation lenses inform development priorities, clinical guidance alignment and product positioning for diverse stakeholder needs.
Comparative regional perspectives on therapeutic access, manufacturing hubs, regulatory environments, and adoption patterns across Americas, EMEA and Asia-Pacific
Regional dynamics continue to determine access, regulation, and manufacturing strategy for corticosteroid therapies, with clear variations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical guidelines and payer systems emphasize evidence of comparative safety and cost-effective delivery, and the region hosts both large-scale manufacturing and concentrated clinical trial activity. Europe, the Middle East & Africa exhibit a complex regulatory mosaic where harmonization efforts and national reimbursement frameworks influence product introductions and post-market surveillance priorities; manufacturers often navigate multiple national requirements while adapting labeling and risk management approaches.
In the Asia-Pacific region, rapid growth in manufacturing capacity, active generic competition, and evolving regulatory sophistication are shaping supply chain decisions and product lifecycle strategies. Patient demographics and healthcare delivery models across these regions create divergent demand patterns, with implications for formulation preferences, device adoption, and the prioritization of training and adherence programs. Consequently, companies and health systems must align commercial tactics and clinical support to the specific regulatory, reimbursement, and care-delivery contours of each region to achieve durable therapeutic impact and operational resilience.
Insights into competitive positioning, R&D prioritization, manufacturing scale, and partnership strategies shaping company performance in corticosteroid care
Company strategies in corticosteroid therapy are being defined by choices in R&D focus, manufacturing footprint, and partnership models that deliver clinical differentiation and operational scale. Leading firms prioritize investment in safer, targeted formulations and device integration to enhance adherence and reduce systemic exposure. They also seek manufacturing flexibility through multi-sourcing arrangements and geographically distributed facilities to mitigate supply risks and respond to regional regulatory requirements. In parallel, companies leverage strategic alliances and licensing agreements to expand therapeutic portfolios or to access complementary technologies for delivery and monitoring.
Commercial differentiation increasingly relies on demonstrating real-world safety data, patient support services, and outcome-oriented value propositions rather than solely on traditional product attributes. Firms that excel combine clinical evidence generation with pragmatic operational capabilities, including robust pharmacovigilance, regulatory intelligence, and nimble supply chain management. These integrated capabilities enable faster response to clinical guidance changes, tariff and trade adjustments, and evolving payer expectations, thereby strengthening competitive positioning in a therapeutic area where long-established products must be continually optimized for modern care settings.
Clear, actionable recommendations for executives and clinical leaders to optimize product portfolios, supply resilience and patient-centric care
Industry leaders should pursue pragmatic, high-impact actions that align clinical excellence with operational resilience. First, prioritize formulation and delivery investments that demonstrably reduce systemic exposure while preserving or enhancing efficacy; such investments should be paired with robust safety monitoring and evidence generation to secure clinician confidence. Second, strengthen supply chain visibility and diversification by identifying critical supplier tiers, increasing geographic redundancy for key inputs, and establishing contractual safeguards against tariff volatility and logistics disruptions. These moves will reduce vulnerability to sudden policy or trade shifts and ensure continuity of patient care.
Beyond operational adjustments, executives should adopt patient-centric commercial strategies that integrate adherence support, device training, and outcome tracking to differentiate offerings in crowded therapeutic categories. Regulatory engagement and proactive pharmacovigilance must remain central, with structured plans to respond to guidance changes and to communicate risk mitigation clearly to prescribers. Finally, cultivate selective partnerships and licensing arrangements that accelerate access to complementary technologies or regional manufacturing capabilities, thereby enabling scalable responses to both clinical and commercial challenges.
Robust research methodology detailing data sources, evidence synthesis, stakeholder interviews and analytical approaches to ensure rigor and transparency
This research synthesizes primary and secondary evidence using a mixed-methods approach that emphasizes transparency, reproducibility, and methodological rigor. Data inputs include peer-reviewed clinical literature, regulatory guidance documents, product labeling and safety advisories, supply chain records, and qualitative interviews with clinicians, supply chain managers, and industry experts. Evidence synthesis combines thematic analysis of qualitative inputs with structured appraisal of clinical sources to ensure that interpretations are grounded in high-quality information and clinician practice realities.
Analytical approaches employ comparative assessment frameworks to evaluate formulation attributes, route-specific advantages, and operational constraints. Sensitivity checks and cross-validation against independent sources were applied where applicable to verify findings and reduce bias. Throughout, methodology choices were guided by the objective of producing actionable intelligence that balances clinical nuance with operational practicality, ensuring that recommendations remain useful to both medical leaders and commercial decision-makers.
Concise conclusion synthesizing clinical implications, operational priorities and strategic next steps for stakeholders in the evolving corticosteroid landscape
In synthesis, corticosteroid therapy continues to occupy a pivotal role across diverse clinical settings, and recent shifts in formulation science, regulatory focus, and supply chain dynamics are reshaping how these medicines are developed and delivered. Clinical decision-making is increasingly informed by considerations of systemic exposure, patient age and comorbidities, and the relative advantages of route-specific delivery. Operationally, organizations must balance manufacturing scale with supply chain flexibility to withstand trade policy shifts and logistical challenges.
Strategically, the most resilient approaches integrate targeted formulation innovation, evidence-driven safety communication, and proactive supply chain management. Executives and clinical leaders who align product development with pragmatic deployment strategies-supported by robust regulatory engagement and patient-centric services-will be best positioned to sustain therapeutic impact and organizational agility. The insights provided here are intended to guide those next steps and to support informed decisions across clinical, operational, and commercial domains.
Note: PDF & Excel + Online Access - 1 Year
A comprehensive introduction to corticosteroid therapy outlining mechanisms of action, clinical indications, safety considerations, and strategic implications
Corticosteroid therapy remains a cornerstone across a wide range of inflammatory and immune-mediated conditions, with clinical practice centering on balancing therapeutic efficacy against safety and long-term risk mitigation. This introduction frames corticosteroids through their pharmacologic mechanisms of action, including glucocorticoid receptor modulation and downstream effects on gene transcription that limit pro-inflammatory cytokine production. It also situates corticosteroids within current therapeutic paradigms where they are used both as acute rescue medications and as components of chronic disease management, highlighting the importance of route selection, formulation innovation, and stewardship to reduce adverse effects.
Transitioning from mechanism to practice, this section explores how clinicians evaluate benefit–risk when selecting inhaled, oral, topical or injectable corticosteroids, and how patient factors such as age, comorbidities, and concomitant therapies influence regimen design. It also underscores operational considerations for supply chain continuity, formulation stability, and regulatory compliance that underpin reliable therapy delivery. Finally, the introduction sets expectations for the subsequent sections by outlining the intersections between clinical evolution, commercial strategy, and policy dynamics that will determine how corticosteroid therapy is delivered and optimized across care settings.
Emerging clinical advances, formulation innovations, and regulatory recalibrations reshaping corticosteroid therapy delivery and patient care decision frameworks
The corticosteroid landscape is experiencing transformative shifts driven by advances in formulation science, changing regulatory emphasis on safety and appropriate use, and improvements in delivery technologies that increase therapeutic precision. In recent years, the industry has accelerated development of targeted inhalation devices, fine-tuned topical formulations with enhanced skin tolerability, and optimized parenteral options that facilitate outpatient administration, thereby broadening the contexts in which corticosteroids can be deployed effectively. These changes reduce systemic exposure for many indications and make it possible to tailor therapy more closely to disease biology and patient preferences.
Concurrently, regulators and professional societies have placed stronger emphasis on stewardship, appropriate tapering protocols, and monitoring of cumulative steroid exposure. This has catalyzed clinical guidance updates and influenced prescriber behavior, encouraging dose minimization where possible and the adoption of nonsteroidal adjuncts. Commercially, pharmaceutical developers are responding with differentiation strategies that emphasize improved safety profiles, convenience of use, and lifecycle management through combination products or device-enabled delivery. Taken together, these forces are reshaping how corticosteroid therapies are developed, positioned, and utilized across care pathways, with implications for clinical outcomes, patient experience, and organizational strategy.
Assessment of how 2025 United States tariff adjustments influence corticosteroid supply chains, import dependencies and manufacturing strategies
Policy shifts in tariff regimes and trade policy can exert rapid effects on pharmaceutical supply chains and the movement of active pharmaceutical ingredients and finished products. In 2025, adjustments to tariff schedules present potential disruptions for companies that rely on cross-border sourcing of corticosteroid APIs, excipients, and specialized packaging. Changes in import duties will influence procurement strategies, prompting manufacturers and distributors to reassess supplier diversity, nearshoring options, and third-party logistics arrangements to preserve continuity of supply and control input costs.
As a consequence, stakeholders are placing greater emphasis on supply chain mapping, visibility into supplier tier risks, and contractual mechanisms that mitigate exposure to sudden cost shifts. Regulatory compliance and tariff classification reviews are becoming routine elements of commercial planning, and organizations are strengthening scenario planning capabilities to respond to customs adjustments or administrative delays. From a clinical perspective, procurement stability is critical because any interruption to product availability can necessitate rapid therapeutic substitutions, with attendant impacts on dosing, monitoring, and patient adherence. Overall, tariff-related dynamics in 2025 are accelerating strategic shifts toward supply resilience, diversified sourcing, and operational flexibility across the corticosteroid value chain.
Strategic segmentation analysis revealing differentiated clinical, formulation, administration route, dosage, and demographic drivers shaping corticosteroid therapy
A nuanced segmentation framework reveals how therapeutic choice and service delivery are shaped by administration route, indication, drug type, dosage form, and patient age group. When considering route of administration, inhalation approaches including dry powder inhaler, metered dose inhaler and nebulizer are prioritized for airway diseases where targeted pulmonary deposition reduces systemic exposure, while injectable options such as intramuscular, intravenous and subcutaneous routes are selected for rapid systemic control or for settings requiring parenteral therapy. Oral formulations differentiated into suspension and tablet support convenience and chronic dosing, and topical preparations in cream, lotion and ointment formats allow localized management of dermatological conditions.
Indication-based segmentation spans allergic rhinitis, asthma, dermatological disorders, inflammatory bowel disease and rheumatoid arthritis, and the clinical imperatives for efficacy and safety differ markedly across these diagnoses. Drug-type differentiation among budesonide, dexamethasone, hydrocortisone, methylprednisolone and prednisone reflects distinct potency, half-life and receptor affinities that drive dosing strategies and monitoring needs. Dosage form distinctions across cream, injection, suspension and tablet have implications for pharmacokinetics and patient adherence, while patient age group segmentation across adult, geriatric and pediatric populations necessitates tailored dosing, safety surveillance and formulation design. Collectively, these segmentation lenses inform development priorities, clinical guidance alignment and product positioning for diverse stakeholder needs.
Comparative regional perspectives on therapeutic access, manufacturing hubs, regulatory environments, and adoption patterns across Americas, EMEA and Asia-Pacific
Regional dynamics continue to determine access, regulation, and manufacturing strategy for corticosteroid therapies, with clear variations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical guidelines and payer systems emphasize evidence of comparative safety and cost-effective delivery, and the region hosts both large-scale manufacturing and concentrated clinical trial activity. Europe, the Middle East & Africa exhibit a complex regulatory mosaic where harmonization efforts and national reimbursement frameworks influence product introductions and post-market surveillance priorities; manufacturers often navigate multiple national requirements while adapting labeling and risk management approaches.
In the Asia-Pacific region, rapid growth in manufacturing capacity, active generic competition, and evolving regulatory sophistication are shaping supply chain decisions and product lifecycle strategies. Patient demographics and healthcare delivery models across these regions create divergent demand patterns, with implications for formulation preferences, device adoption, and the prioritization of training and adherence programs. Consequently, companies and health systems must align commercial tactics and clinical support to the specific regulatory, reimbursement, and care-delivery contours of each region to achieve durable therapeutic impact and operational resilience.
Insights into competitive positioning, R&D prioritization, manufacturing scale, and partnership strategies shaping company performance in corticosteroid care
Company strategies in corticosteroid therapy are being defined by choices in R&D focus, manufacturing footprint, and partnership models that deliver clinical differentiation and operational scale. Leading firms prioritize investment in safer, targeted formulations and device integration to enhance adherence and reduce systemic exposure. They also seek manufacturing flexibility through multi-sourcing arrangements and geographically distributed facilities to mitigate supply risks and respond to regional regulatory requirements. In parallel, companies leverage strategic alliances and licensing agreements to expand therapeutic portfolios or to access complementary technologies for delivery and monitoring.
Commercial differentiation increasingly relies on demonstrating real-world safety data, patient support services, and outcome-oriented value propositions rather than solely on traditional product attributes. Firms that excel combine clinical evidence generation with pragmatic operational capabilities, including robust pharmacovigilance, regulatory intelligence, and nimble supply chain management. These integrated capabilities enable faster response to clinical guidance changes, tariff and trade adjustments, and evolving payer expectations, thereby strengthening competitive positioning in a therapeutic area where long-established products must be continually optimized for modern care settings.
Clear, actionable recommendations for executives and clinical leaders to optimize product portfolios, supply resilience and patient-centric care
Industry leaders should pursue pragmatic, high-impact actions that align clinical excellence with operational resilience. First, prioritize formulation and delivery investments that demonstrably reduce systemic exposure while preserving or enhancing efficacy; such investments should be paired with robust safety monitoring and evidence generation to secure clinician confidence. Second, strengthen supply chain visibility and diversification by identifying critical supplier tiers, increasing geographic redundancy for key inputs, and establishing contractual safeguards against tariff volatility and logistics disruptions. These moves will reduce vulnerability to sudden policy or trade shifts and ensure continuity of patient care.
Beyond operational adjustments, executives should adopt patient-centric commercial strategies that integrate adherence support, device training, and outcome tracking to differentiate offerings in crowded therapeutic categories. Regulatory engagement and proactive pharmacovigilance must remain central, with structured plans to respond to guidance changes and to communicate risk mitigation clearly to prescribers. Finally, cultivate selective partnerships and licensing arrangements that accelerate access to complementary technologies or regional manufacturing capabilities, thereby enabling scalable responses to both clinical and commercial challenges.
Robust research methodology detailing data sources, evidence synthesis, stakeholder interviews and analytical approaches to ensure rigor and transparency
This research synthesizes primary and secondary evidence using a mixed-methods approach that emphasizes transparency, reproducibility, and methodological rigor. Data inputs include peer-reviewed clinical literature, regulatory guidance documents, product labeling and safety advisories, supply chain records, and qualitative interviews with clinicians, supply chain managers, and industry experts. Evidence synthesis combines thematic analysis of qualitative inputs with structured appraisal of clinical sources to ensure that interpretations are grounded in high-quality information and clinician practice realities.
Analytical approaches employ comparative assessment frameworks to evaluate formulation attributes, route-specific advantages, and operational constraints. Sensitivity checks and cross-validation against independent sources were applied where applicable to verify findings and reduce bias. Throughout, methodology choices were guided by the objective of producing actionable intelligence that balances clinical nuance with operational practicality, ensuring that recommendations remain useful to both medical leaders and commercial decision-makers.
Concise conclusion synthesizing clinical implications, operational priorities and strategic next steps for stakeholders in the evolving corticosteroid landscape
In synthesis, corticosteroid therapy continues to occupy a pivotal role across diverse clinical settings, and recent shifts in formulation science, regulatory focus, and supply chain dynamics are reshaping how these medicines are developed and delivered. Clinical decision-making is increasingly informed by considerations of systemic exposure, patient age and comorbidities, and the relative advantages of route-specific delivery. Operationally, organizations must balance manufacturing scale with supply chain flexibility to withstand trade policy shifts and logistical challenges.
Strategically, the most resilient approaches integrate targeted formulation innovation, evidence-driven safety communication, and proactive supply chain management. Executives and clinical leaders who align product development with pragmatic deployment strategies-supported by robust regulatory engagement and patient-centric services-will be best positioned to sustain therapeutic impact and organizational agility. The insights provided here are intended to guide those next steps and to support informed decisions across clinical, operational, and commercial domains.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Impact of targeted inhaled corticosteroid formulations on severe asthma management costs and outcomes
- 5.2. Emerging small-molecule glucocorticoid receptor modulators aiming to reduce systemic side effects in chronic inflammatory diseases
- 5.3. Expansion of biosimilar corticosteroid injectables improving access in emerging markets and driving price competition
- 5.4. Development of nanotechnology-based corticosteroid drug delivery systems for enhanced ocular and dermal therapy efficacy
- 5.5. Integration of digital health platforms for remote monitoring of biologic corticosteroid therapy adherence in rheumatoid arthritis
- 5.6. Growing adoption of combination corticosteroid and immunomodulator therapies for atopic dermatitis with improved patient adherence
- 5.7. Regulatory changes accelerating approval pathways for novel inhaled corticosteroid therapies targeting pediatric asthma populations
- 5.8. Advancements in gene expression profiling guiding personalized dosing strategies for systemic corticosteroid regimens in autoimmune conditions
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Corticosteroids Therapy Market, by Drug Type
- 8.1. Budesonide
- 8.2. Dexamethasone
- 8.3. Hydrocortisone
- 8.4. Methylprednisolone
- 8.5. Prednisone
- 9. Corticosteroids Therapy Market, by Route Of Administration
- 9.1. Inhalation
- 9.1.1. Dry Powder Inhaler
- 9.1.2. Metered Dose Inhaler
- 9.1.3. Nebulizer
- 9.2. Injectable
- 9.2.1. Intramuscular
- 9.2.2. Intravenous
- 9.2.3. Subcutaneous
- 9.3. Oral
- 9.3.1. Suspension
- 9.3.2. Tablet
- 9.4. Topical
- 9.4.1. Cream
- 9.4.2. Lotion
- 9.4.3. Ointment
- 10. Corticosteroids Therapy Market, by Dosage Form
- 10.1. Cream
- 10.2. Injection
- 10.3. Suspension
- 10.4. Tablet
- 11. Corticosteroids Therapy Market, by Indication
- 11.1. Allergic Rhinitis
- 11.2. Asthma
- 11.3. Dermatological Disorders
- 11.4. Inflammatory Bowel Disease
- 11.5. Rheumatoid Arthritis
- 12. Corticosteroids Therapy Market, by Patient Age Group
- 12.1. Adult
- 12.2. Geriatric
- 12.3. Pediatric
- 13. Corticosteroids Therapy Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Corticosteroids Therapy Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Corticosteroids Therapy Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Abbott Laboratories
- 16.3.2. Allergan PLC by AbbVie Inc.
- 16.3.3. Amgen Inc.
- 16.3.4. AstraZeneca PLC
- 16.3.5. Biogen Inc.
- 16.3.6. Boehringer Ingelheim GmbH
- 16.3.7. Bristol-Myers Squibb Company
- 16.3.8. Cipla Inc.
- 16.3.9. Dr. Reddy's Laboratories Ltd.
- 16.3.10. Eli Lilly and Company
- 16.3.11. Galderma Group
- 16.3.12. Gilead Sciences, Inc.
- 16.3.13. GlaxoSmithKline PLC
- 16.3.14. Lupin Pharmaceuticals, Inc.
- 16.3.15. Merck & Co., Inc.
- 16.3.16. Mylan N.V.
- 16.3.17. Novartis AG
- 16.3.18. Pfizer Inc.
- 16.3.19. Sanofi S.A.
- 16.3.20. SANTHERA PHARMACEUTICALS
- 16.3.21. Sun Pharmaceutical Industries Ltd.
- 16.3.22. Takeda Pharmaceutical Company Limited
- 16.3.23. Teva Pharmaceutical Industries Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
